Literature DB >> 1254945

Transformation of human peripheral lymphocytes by galactose oxidase.

J F Dixon, J W Parker, R L O'Brien.   

Abstract

Human peripheral lymphocytes can be transformed by treatment with galactose oxidase alone. Prior treatment with neuraminidase enhances this effect. The aldehyde blocking agents thiocarbohydrazide, hydroxylamine, dimedone, and sodium borohydride block transformation when they follow, but not when they precede, galactose oxidase treatment. Thus, as is the case for periodate-induced lymphocyte transformation, the formation of free aldehyde at the cell surface would seem to be a critical event in the triggering of transformation by this agent. The degree of transformation is highly variable from individual to individual, and also for the same donor at different times. However, the lymphocytes of some people give a consistently poor response to galactose oxidase. Similar results have been obtained for periodate-induced transformation of human lymphocytes, but to this date this is unexplained.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1254945

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  Mitogenic action of neuraminidase.

Authors:  G Semenzato; P Sarasin; G Amadori; G Gasparotto
Journal:  Experientia       Date:  1977-11-15

2.  Effect of corticosteroids on the response of lymphocytes to stimulation by galactose oxidase-modified lymphocytes.

Authors:  D T Yu; S J Ramer; A Kacena
Journal:  Immunology       Date:  1977-08       Impact factor: 7.397

3.  Enzymatic induction of interferon production by galactose oxidase treatment of human lymphoid cells.

Authors:  F Dianzani; T M Monahan; A Scupham; M Zucca
Journal:  Infect Immun       Date:  1979-12       Impact factor: 3.441

4.  Mycoplasma interaction with lymphocytes and phagocytes: role of hydrogen peroxide released from M. pneumoniae.

Authors:  S Arai; T Munakata; K Kuwano
Journal:  Yale J Biol Med       Date:  1983 Sep-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.